Sridevi Rajeeve, MD
@sridevirajeeve
Followers
2K
Following
9K
Statuses
1K
⚕️Asst. Attending Myeloma & Cell Therapy @MSKCancerCenter via @MountSinaiNYC @TischCancer 🇮🇳➡️🇺🇸 Interests: #MMsm #CART #cellulartherapy
New York, NY
Joined August 2009
Amazing evening receiving the @ASCO @ConquerCancerFd Young Investigator Award (YIA) 2022. Thankful to my stellar mentor Dr. Samir Parekh at @IcahnMountSinai & @TischCancer @SinaiHemeOnc for the support! #ASCO22 📸3: friends, old and new @drsomedeb 📸4: proud hubby @suchithnair
10
3
99
@RahulBanerjeeMD IVIg denials have been increasing. I aggressively document necessity (IVIg levels, Tx type, # infections) and now denials at each time point. Coz - accountability.
1
2
2
@KRejeski @RahulBanerjeeMD @LMU_Muenchen Congratulations and well deserved! Looking forward to amazing science.
0
0
2
RT @RahulBanerjeeMD: So excited!! Welcome @UrviShahMD to @fredhutch Grand Rounds. I’m glad you joined by Zoom since shockingly it is rainin…
0
6
0
RT @szusmani: We are excited to have you @FrancescoMaura4, lot of work ahead! #mmsm @MSK_DeptOfMed @MSKCancerCenter @UrviShahMD @CarlynRTan…
0
5
0
RT @MSKCancerCenter: MSK is the first hospital in New York City to offer gene therapy for #sicklecelldisease and beta thalassemia through i…
0
8
0
RT @JoshuaRichterMD: Congrats to @RahulBanerjeeMD @VincentRK @szusmani @Myeloma_Doc @myelomaMD et al for this extremely clinicall…
0
29
0
#ASH24 📊: Daratumumab vs lenalidomide maintenance in NDMM TE+TI, 1:1 randomized IIT @MSKCancerCenter. n=87 (39 dara, 38 len). Similar (numerically ⬆️) 12mPFS, 24mPFS, >=CR & MRD- rates with fewer drug discontinuation on dara arm. 66% prior dara exposure. @UrviShahMD @szusmani
4
8
46
RT @VincentRK: Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24
@thanosdimop @NEJM Daratumumab…
0
127
0
RT @RahulBanerjeeMD: Out in @NEJM as @thanosdimop is speaking!! 🚨 Most important #ASH24 abstract in #MMsm: AQUILA study demonstrating OS b…
0
17
0
RT @RahulBanerjeeMD: 1/ Easily the most provocative #MMsm oral abstract of #ASH24 🤔 Does transplantation interfere with subsequent CAR-T e…
0
22
0
RT @bdermanmd: What happens when patients with myeloma and sustained MRD negativity choose to discontinue maintenance? We sought to answer…
0
52
0
RT @MSK_DeptOfMed: Join myeloma specialist Dr. Kylee Maclachlan for the presentation "Genomic Complexity Correlates with the Degree of Marr…
0
4
0
RT @hhashmi87: Hot off the press in @BloodCancerJnl Salvage therapy for post CAR T relapse: Are BiTES the right choice? n=139 (mostly idec…
0
8
0
@mdbrunocosta @MDAndersonNews Congratulations & well deserved Bruno! 🥳Proud to see @msm_msw alumni excel!
1
0
3
🎃 Halloween ft. MSK #MyelomaService. How many costumes can you spot? @MSK_DeptOfMed @MSKCancerCenter @szusmani @MalinHultcrantz @CarlynRTanMD @HassounHani #ShamMailankody @RossFirestone @EricJurgens1
0
2
19
RT @RahulBanerjeeMD: 1/ 🚨 Now in @BloodCancerJnl - our multicenter description of IEC-associated enterocolitis as a novel toxicity of CAR-T…
0
46
0
RT @ChenyuLinMD: Recently saw a study co-authored by @DukeHMCT @tomleblancMD surveying #MMsm patients & caregivers. ➡️Patients care more…
0
8
0